Hoth Therapeutics shareholders reject reverse stock split; Nasdaq compliance at risk

Hoth Therapeutics, Inc.

Shareholders re-elected directors Robb Knie, David Sarnoff, Graig Springer, Wayne Linsley.
Ratified Withum as independent auditor for FY2022; approved 2022 Omnibus Equity Incentive Plan.
Reverse stock split proposal (1:2 to 1:20) failed, with 13,162,362 for, 3,116,563 against.
Nasdaq minimum bid price compliance deadline is June 28, 2022; company considers special meeting to revisit reverse split.
Failure to regain compliance could result in delisting from Nasdaq.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.